New medication plus standard treatment for advanced prostate cancer

Plain-English translation of NCT07213674 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a Phase 3 trial testing a new medication called combined with abiraterone (a standard prostate cancer drug) in men with advanced, treatment-resistant prostate cancer. About 750 men will be enrolled. Half will receive the new combination treatment, and half will receive their doctor's choice of current standard treatments.

Men with advanced prostate cancer that has stopped responding to hormone therapy need better treatment options. This medication is being tested to see if it can help people live longer and control their cancer better than treatments currently available.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy)
you have already tried and failed at least one hormone-blocking therapy
you have evidence that your cancer is growing despite hormone treatment
you have not received chemotherapy drugs for advanced prostate cancer before
you are at least 18 years old and in good enough health to tolerate cancer treatment

You likely don't qualify if…

you have cancer that has spread to your brain or central nervous system
you have already tried abiraterone and it stopped working for you
you have received chemotherapy drugs to treat advanced prostate cancer
you have unresolved side effects from previous cancer treatments
you are currently taking another investigational cancer drug or have taken one in the past 4 weeks

What participation looks like

If you join this trial, you will be randomly assigned to either receive the new medication plus abiraterone, or one of your doctor's choice of current standard treatments. You will have regular clinic visits for blood tests, imaging scans, and check-ins to see how you are tolerating treatment and how your cancer is responding. The trial continues until your cancer progresses or you experience unacceptable side effects.

AI-generated summary from trial data · Aug 20, 2026 · Not medical advice

Trial locations(155 sites)

United States

City of Hope Cancer Center Phoenix, Goodyear, Arizona

University of Arizona Cancer Center, Tucson, Arizona

City of Hope National Medical Center, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center, Duarte, California

Providence Saint Jude Medical Center, Fullerton, California